The Leukemia & Lymphoma Society funds leading-edge research for every type of blood cancer, including leukemia, lymphoma, myeloma, and other rare types of blood cancers. As the largest nonprofit funder of cutting-edge blood cancer research to advance cures, LLS has invested nearly $1.3 billion in cancer research since we started in 1949, leading to breakthroughs in immunotherapy, genomics and personalized medicine that are improving and saving the lives of patients.
LLS helped advance 44 of the 50 blood cancer treatment options approved by the FDA since 2017 through today.

LLS has invested $1.3 billion in cancer research since its founding in 1949, leading to nearly every advancement in blood cancer treatment and breakthroughs in immunotherapy, genomics and personalized medicine. LLS' support of pioneering research at nearly 100 medical institutions worldwide is breaking new ground in the fight against cancer.